Enable JavaScript to visit this website.
Please use Landscape mode or tablet for convenience!
Back to top

FOR YOUR PATIENTS AGED 65 AND OLDER

INDICATION

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of
    pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

IMPORTANT SAFETY INFORMATION

  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication

  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response

  • In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.

Models used for illustrative purposes only. Information is hypothetical and not based on actual Prevnar 13® patients.

Level: {{prevnar.level.levelName?prevnar.level.levelName: '1'}}
Score: {{prevnar.score}}
{{question.questionPatientName}} {{question.questionPatientAge?question.questionPatientAge+' years old':''}}

{{question.questionEmc?"Existing Medical Conditions":""}}

{{question.questionPvh?"Pneumococcal Vaccination History":""}}

Body: 

INSTRUCTIONS

SHOT OR NOT can help you become familiar with the CDC’s ACIP pneumococcal recommendations for immunocompetent adults aged 65 and older. The objective of this is to help you identify which pneumococcal vaccination, when appropriate, should be administered TODAY based on the CDC’s ACIP recommendations for immunocompetent adults aged 65 and older. Please keep in mind it does not take into consideration subsequent doses that may be recommended at a later date.
  1. When you click “START”, you will be presented with a fictional patient profile. Based on the information provided and the CDC's ACIP pneumococcal recommendations, choose which vaccination option should be recommended for this patient today:
    • Prevnar 13®
    • Pneumovax® 23
    • None
  2. Once you select your option, press “SUBMIT”. You will then be greeted with a pop-up explaining whether your selection aligns with the official recommendations from the CDC’s ACIP.
  3. To advance to the next patient profile, tap the “SPIN” button.

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.
Pneumovax is a registered trademark of Merck & Co., Inc.

Body: 

INDICATION

  • In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

IMPORTANT SAFETY INFORMATION

  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

In using this application, you agree that neither Pfizer nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or not taken due to your use of information presented through this application.

NO STATEMENTS MADE IN THIS APPLICATION HAVE BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION.

Please note, you may report an adverse event related to any Pfizer product by calling Pfizer at 1-800-438-1985. Or, if you prefer, you may contact the Food and Drug Administration directly by visiting www.fda.gov/medwatch, or calling 1-800-FDA-1088.

Prescribing Information Continue

Manufactured by Wyeth Pharmaceuticals Inc.

  • © 2017 Pfizer Inc.
  • PP-PNA-USA-2301-01
  • All rights reserved.
  • Marketed by Pfizer Inc.
    March 2017

 

References
Body: 
  1. Jain S, Self WH, Wunderink RG, et al; for the CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.
  2. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1-9. doi:10.1093/ofid/ofu024.
  3. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64(34):944-947.
  4. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-825.
  5. Centers for Disease Control and Prevention (CDC). General recommendations on immunization. MMWR Morb Mortal Wkly Rep. 2011;60(2):1-64.

You Are Now Leaving SHOT OR NOT

You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.